Develops oral vaccines for norovirus and coronavirus.
Jun 2026Revenue $243M/yrExpenses $203M/yr
Reached break-even Dec 2025
Figures by year
When did Vaxart become profitable?
Its revenue passed its expenses in Dec 2025. In the 12 months to Jun 2026, revenue was $243M and expenses $203M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $237M | $219M | $18.1M |
| Dec 2024 | $28.7M | $95.0M | −$66.3M |
| Dec 2023 | $7.38M | $90.7M | −$83.3M |
| Dec 2022 | $107K | $115M | −$115M |
| Dec 2021 | $892K | $73.6M | −$72.8M |
| Dec 2020 | $4.05M | $34.2M | −$30.2M |
| Dec 2019 | $9.86M | $25.6M | −$15.8M |
| Dec 2018 | $4.16M | $25.9M | −$21.8M |
| Dec 2017 | $5.84M | $15.9M | −$10.0M |
| Jun 2017 | $8.90M | $36.4M | −$27.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.